Characterizing the outcomes of metastatic papillary renal cell carcinoma

被引：37

作者：

Wells, John Connor ^{[1
,2
]}

Donskov, Frede ^{[3
]}

Fraccon, Anna P. ^{[4
]}

Pasini, Felice ^{[5
]}

Bjarnason, Georg A. ^{[6
]}

Beuselinck, Benoit ^{[7
]}

Knox, Jennifer J. ^{[8
]}

Rha, Sun Young ^{[9
]}

Agarwal, Neeraj ^{[10
]}

Bowman, Isaac Alex ^{[11
]}

Lee, Jae-Lyun ^{[12
]}

Pal, Sumanta K. ^{[13
]}

Srinivas, Sandy ^{[14
]}

Ernst, Douglas Scott ^{[15
]}

Vaishampayan, Ulka N. ^{[16
]}

Wood, Lori A. ^{[17
]}

Simpson, Robin ^{[17
]}

De Velasco, Guillermo ^{[18
]}

Choueiri, Toni K. ^{[18
]}

Heng, Daniel Y. C. ^{[1
]}

机构：

[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[2] Queens Univ, Kingston, ON, Canada

[3] Aarhus Univ Hosp, Aarhus, Denmark

[4] Casa Cura Pederzoli, Peschiera Del Garda, Italy

[5] Osped Santa Maria Misericordia, Med Oncol Dept, Rovigo, Italy

[6] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Princess Margaret Hosp, Toronto, ON, Canada

[9] Yonsei Univ, Coll Med, Seoul, South Korea

[10] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[11] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[12] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[13] City Hope Comprehens Canc Ctr, Duarte, CA USA

[14] Stanford Canc Ctr, Stanford, CA USA

[15] London Hlth Sci Ctr, London, ON, Canada

[16] Karmanos Canc Inst, Detroit, MI USA

[17] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[18] Dana Farber Canc Inst, Boston, MA USA

来源：

CANCER MEDICINE | 2017年 / 6卷 / 05期

关键词：

Metastatic renal cell carcinoma; outcomes; papillary; response rate; survival; targeted therapy; PHASE-II; OPEN-LABEL; SUNITINIB; SURVIVAL; TRIAL; EVEROLIMUS; NONCLEAR; EFFICACY; TYPE-1; MULTICENTER;

D O I：

10.1002/cam4.1048

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.

引用

页码：902 / 909

页数：8

共 50 条

[31] Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors [J].

Graham, Jeffrey ;

Shah, Amishi Y. ;

Wells, J. Connor ;

McKay, Rana R. ;

Vaishampayan, Ulka ;

Hansen, Aaron ;

Donskov, Frede ;

Bjarnason, Georg A. ;

Beuselinck, Benoit ;

De Velasco, Guillermo ;

Iafolla, Marco ;

Duh, Mei S. ;

Huynh, Lynn ;

Chang, Rose ;

Zanotti, Giovanni ;

Ramaswamy, Krishnan ;

Choueiri, Toni K. ;

Tannir, Nizar M. ;

Heng, Daniel Y. C. .

EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (01) :102-111

[32] Current management of metastatic renal cell carcinoma: evolving new therapies [J].

Kumar, Ravi ;

Kapoor, Anil .

CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2017, 11 (03) :231-237

[33] Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year [J].

Gross-Goupil, Marine ;

Massard, Christophe ;

Ravaud, Alain .

CURRENT UROLOGY REPORTS, 2012, 13 (01) :16-23

[34] Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions [J].

Merza, Hussein ;

Bilusic, Marijo .

CURRENT ONCOLOGY REPORTS, 2017, 19 (04)

[35] Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors [J].

Hanif, Ahmad ;

Pandey, Manu ;

Khan, Sumera ;

Attwood, Kristopher ;

George, Saby .

ONCOIMMUNOLOGY, 2019, 8 (08)

[36] Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib [J].

Keizman, Daniel ;

Sarid, David ;

Lee, Jae L. ;

Sella, Avishay ;

Gottfried, Maya ;

Hammers, Hans ;

Eisenberger, Mario A. ;

Carducci, Michael A. ;

Sinibaldi, Victoria ;

Neiman, Victoria ;

Rosenbaum, Eli ;

Peer, Avivit ;

Neumann, Avivit ;

Mermershtain, Wilmosh ;

Rouvinov, Keren ;

Berger, Raanan ;

Yildiz, Ibrahim .

ONCOLOGIST, 2016, 21 (10) :1212-1217

[37] Real-World Outcome of 173 Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC) Cases: The Experience of the Center Group for Genitourinary Tumors [J].

Martin, Almudena ;

Puente, Javier ;

Pinto, Alvaro ;

Gajate, Pablo ;

Alonso Gordoa, Teresa ;

Grande, Enrique ;

Herrero, Ana ;

Maximiano, Constanza ;

Garrido, Maria ;

Gallegos, Isabel ;

Laura Villalobos, Ma ;

Garcia-Donas, Jesus ;

Caviedes, Edinson ;

Garcia, Iciar ;

Espinosa, Javier ;

Aguado, Carlos ;

Angel Arranz, Jose ;

Garcia, Lourdes ;

Francisco Rodriguez, Juan ;

Casinello, Javier ;

Rodriguez, Laura .

KIDNEY CANCER, 2019, 3 (01) :41-50

[38] Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes [J].

Cella, David .

CANCER TREATMENT REVIEWS, 2009, 35 (08) :733-737

[39] Management of Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib and Clinical Outcomes [J].

Arakawa-Todo, Maki ;

Yoshizawa, Takahiko ;

Zennami, Kenji ;

Nishikawa, Genya ;

Kato, Yoshiharu ;

Kobayashi, Ikuo ;

Kajikawa, Keishi ;

Yamada, Yoshiaki ;

Matsuura, Katsuhiko ;

Tsukiyama, Ikuto ;

Saito, Hiroko ;

Hasegawa, Takaaki ;

Nakamura, Kogenta ;

Sumitomo, Makoto .

ANTICANCER RESEARCH, 2013, 33 (11) :5043-5050

[40] Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials [J].

Heng, D. Y. C. ;

Choueiri, T. K. ;

Rini, B. I. ;

Lee, J. ;

Yuasa, T. ;

Pal, S. K. ;

Srinivas, S. ;

Bjarnason, G. A. ;

Knox, J. J. ;

MacKenzie, M. ;

Vaishampayan, U. N. ;

Tan, M. H. ;

Rha, S. Y. ;

Donskov, F. ;

Agarwal, N. ;

Kollmannsberger, C. ;

North, S. ;

Wood, L. A. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :149-154

← 1 2 3 4 5 →